Kidney cancer survival statistics

Coronavirus (COVID-19)

We have created a central resources hub for Health Professionals which hosts all of our CRUK resources and further materials to help with managing the pandemic. We are updating the information as guidance changes. There is also a page specifically for patients on our about cancer hub.

Health Professional COVID-19 and Cancer Hub

Survival

Survive kidney cancer for 10 or more years, 2013-2017, England

Age

Age that kidney cancer survival is highest, 2009-2013, England

 

Improvement

Kidney cancer survival in the UK has increased in the last 40 years

 

79.2% of males survive kidney cancer for at least one year. This falls to 62.9% surviving for five years or more, as shown by age-standardised net survival for patients diagnosed with kidney cancer during 2013-2017 in England.[1] Survival for females at one year is 79.6% and falls to 65.4% surviving for at least five years. Survival for females is similar to than for males at one year, and higher than for at five years.

Kidney Cancer Age-Standardised One-, Five- and Ten-Year Net Survival, Adults (Aged 15-99), England, 2013-2017

The bar chart shows one- and five-year net survival and predicted ten-year net survival, with 95% confidence intervals. Open a glossary item
 

Kidney cancer survival continues to fall beyond five years after diagnosis. 51.2% of males and 53.1% of females are predicted to survive their disease for ten years or more, as shown by age-standardised net survival for patients diagnosed with kidney cancer during 2013-2017 in England.[1]

References

  1. Office for National Statistics, Cancer survival by stage at diagnosis for England, 2019.

About this data

Data is for England, 2013 - 2017, ICD-10 C67.

Survival statistics give an overall picture of survival and the survival time experienced by an individual patient may be much higher or lower, depending on specific patient and tumour characteristics.

Last reviewed:

Five-year survival for kidney cancer is highest in the youngest men and women and decreases with increasing age. Five-year net survival in men ranges from 74% in 15-49 year-olds to 38% in 80-99 year-olds for patients diagnosed with kidney cancer in England during 2009-2013.[1] In women, five-year survival ranges from 81% to 33% in the same age groups.

Kidney Cancer (C64-C66 and C68), Five-Year Net Survival by Age, England, 2009-2013

References

  1. Office for National Statistics. Cancer survival in England: adults diagnosed in 2009 to 2013,followed up to 2014. Newport: ONS; 2015.

About this data

Data is for: England, 2009-2013, ICD-10 C64-C66 and C68

Last reviewed:

As with most cancers, survival for kidney cancer is improving. One-year age-standardised net survival for kidney cancer in men has increased from 45% during 1971-1972 to 73% during 2010-2011 in England and Wales – an absolute survival difference Open a glossary item of 28 percentage points.[1] In women, one-year survival has increased from 44% to 71% over the same time period (a difference of 27 percentage points).

Kidney Cancer (C64-C66 and C68), Age-Standardised One-Year Net Survival, Adults (Aged 15-99), England and Wales, 1971-2011

Five-year age-standardised net survival for kidney cancer in men has increased from 29% during 1971-1972 to a predicted survival of 57% during 2010-2011 in England and Wales – an absolute survival difference of 28 percentage points.[1] In women, five-year survival has increased from 28% to 56% over the same time period (a difference of 28 percentage points).

Kidney Cancer (C64-C66 and C68), Age-Standardised Five-Year Net Survival, Adults (Aged 15-99), England and Wales, 1971-2011

Five-year survival for 2010-2011 is predicted using an excess hazard statistical model

Ten-year survival has followed the same trend as one- and five-year survival since the early 1970s. Ten-year age-standardised net survival for kidney cancer in men has increased from 23% during 1971-1972 to a predicted survival of 50% during 2010-2011 in England and Wales - an absolute survival difference of 27 percentage points.[1] In women, ten-year survival has increased from 23% to 49% over the same time period (a difference of 26 percentage points). Overall, half of people diagnosed with kidney cancer today are predicted to survive their disease for at least ten years.

Kidney Cancer (C64-C66 and C68), Age-Standardised Ten-Year Net Survival, Adults (Aged 15-99), England and Wales, 1971-2011

Ten-year survival for 2005-2006 and 2010-2011 is predicted using an excess hazard statistical model

References

  1. Data were provided by London School of Hygiene and Tropical Medicine on request, 2014.

About this data

Data is for: England and Wales, 1971-2011, ICD-10 C64-C66 and C68

Last reviewed:

Survival for kidney cancer is related to stage of the disease at diagnosis.

One-year net survival by stage

One-year net survival for kidney cancer is highest for patients diagnosed at Stage 1, and lowest for those diagnosed at Stage 4, as 2013-2017 data for England show.[1] 96% of patients diagnosed at Stage 1 survived their disease for at least one year, compared to 39% of patients diagnosed at Stage 4.[1]

One year net survival for unknown or missing stage is 73%, while one year survival for unstageable cancer is 67%. Lack of staging information may in some cases reflect advanced stage at diagnosis as very unwell patients may not undergo staging tests if the invasiveness of the testing outweighs the potential benefit of obtaining stage information. Incomplete staging assessment may also be associated with socio-demographic and clinical characteristics of the patient [2]. Stage completeness for kidney cancer was 84% in 2013-2017 [1].

For patients diagnosed at Stage 3, one-year net survival is significantly higher for males than for females, with an absolute survival difference of 3 percentage points. One-year net survival is also higher for males at Stage 4 (difference of 4 percentage points). One-year net survival is similar for males and females at all other stages[1]

Kidney cancer one-year net survival by stage, with incidence by stage (all data: adults diagnosed 2013-2017, followed up to 2018)

Five-year net survival by stage

Five-year net survival is similar at Stage 1 for males and females. This is also true for Stages 2, 3 and 4. Five-year net survival in males ranges from 86% when diagnosed at Stage 1 to 12% when diagnosed at Stage 4 (an absolute difference of 74 percentage points). Five-year net survival in females ranges from 88% when diagnosed at Stage 1 to 13% when diagnosed at Stage 4 (an absolute difference of 75 percentage points). [1]

Kidney cancer five-year net survival by stage, with incidence by stage (all data: adults diagnosed 2013-2017, followed up to 2018)

References

  1. Office for National Statistics, Cancer survival by stage at diagnosis for England, 2019.
  2. Girolamo, C. et al, Characteristics of patients with missing information on stage: a population-based study of patients diagnosed with a colon, lung or breast cancer in England in 2013, BMC Cancer (2018) 18:492

About this data

Data is for: England, 2013 - 2017, ICD-10 C64.

Survival statistics give an overall picture of survival but the survival time experienced by an individual patient may be much higher or lower, depending on specific patient and tumour characteristics.

Last reviewed:

Five-year relative survival for kidney cancer in men in England (47%) is below the average for Europe (60%). Wales (49%), Scotland (46%) and Northern Ireland (48%) are also below the European average.[1] Across the European countries for which data is available, five-year relative survival in men ranges from 39% (Bulgaria) to 72% (Austria).[1

Five-year relative survival for kidney cancer in women in England (48%) is below the average for Europe (62%). Wales (52%), Scotland (46%) and Northern Ireland (50%) are also below the European average.[1] Across the European countries for which data is available, five-year relative survival in women ranges from 44% (Denmark) to 72% (Austria).[1

Kidney Cancer (C64-C66, C68), Age-Standardised Five-Year Relative Survival, Adults (Aged 15+), European Countries, 2000-2007

Data consists of both observed and predicted 5-year relative survival. Where sufficient follow-up was not available for recently diagnosed patients the period approach was used to predict 5-year cohort survival.

Possible explanations for persistent international differences in survival include differences in cancer biology, use of diagnostic tests and screening, stage at diagnosis, access to high-quality care, and data collection practices.[1]

References

  1. De Angelis R, Sant M, Coleman MP, et al. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5 - a population-based study. Lancet Oncol 2014;15:23-34

About this data

Data is for: 29 European countries, patients diagnosed in 2000-2007 and followed up to 2008, kidney cancer (International Classification of Diseases for Oncology [ICD-O-3] C64-C66, C68).

Last reviewed:

We’re now on twitter.
Join the conversation and follow @CRUKHCPs for news, updates and opinion.

@CRUKHCPs

Cancer stats explained

See information and explanations on terminology used for statistics and reporting of cancer, and the methods used to calculate some of our statistics.

Citation

You are welcome to reuse this Cancer Research UK content for your own work.
Credit us as authors by referencing Cancer Research UK as the primary source. Suggested styles are:

Web content: Cancer Research UK, full URL of the page, Accessed [month] [year].
Publications: Cancer Research UK ([year of publication]), Name of publication, Cancer Research UK.
Graphics (when reused unaltered): Credit: Cancer Research UK.
Graphics (when recreated with differences): Based on a graphic created by Cancer Research UK.

When Cancer Research UK material is used for commercial reasons, we encourage a donation to our life-saving research.
Send a cheque payable to Cancer Research UK to: Cancer Research UK, 2 Redman Place, London, E20 1JQ or

Donate online

Acknowledgements

We are grateful to the many organisations across the UK which collect, analyse, and share the data which we use, and to the patients and public who consent for their data to be used. Find out more about the sources which are essential for our statistics.